Aimed Alliance sent letters to the Maryland PDAB urging it to proceed cautiously with setting a UPL for Jardiance and Farxiga, emphasizing the risk of unintended consequences such as formulary exclusions and harmful non‑medical switching for stable patients. The letters call for robust monitoring mechanisms and clear safeguards to ensure that any UPL does not reduce patient access to necessary therapies. Finally, they stress that patient experiences and feedback must be prioritized and treated as essential evidence throughout the rulemaking process. Read the letters here: Farxiga Letter and Jardiance Letter.
Last Updated on March 18, 2026 by Aimed Alliance
